Tolevamer, a Novel Nonantibiotic Polymer, Compared with Vancomycin in the Treatment of Mild to Moderately Severe Clostridium difficile-Associated Diarrhea
Thomas Louie(Alberta Health Services), Stacey L. Simon(Children's Hospital Colorado), Gary Garber(University of Ottawa), Joseph F. John(Lahey Hospital and Medical Center), Rezika Mohammed(University of Gondar), Jennifer Peppe, Chi‐Leung Watt(Kwong Wah Hospital), David A. Johnson(University of Chicago), K.H. Weiss(Hôpital Maisonneuve-Rosemont), David M. Davidson, Samantha Taber(Helios Klinikum Emil von Behring), G Dow(Moncton Hospital)
Cited by 204
Related Papers
Fidaxomicin versus Vancomycin for <i>Clostridium difficile</i> Infection
|New England Journal of Medicine|2011|1.6k
Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever
|New England Journal of Medicine|2002|986
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
|Circulation|2008|845
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Antimicrobial Resistance in Hospitals
|Clinical Infectious Diseases|1997|783
Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection
|Clinical Infectious Diseases|2011|716